HPTLC DETERMINATION OF CILOSTAZOL IN PHARMACEUTICAL DOSAGE FORMS.

*JOSE KURIEN¹, P. JAYASEKHAR² AND JINU JOHN³

1. College of Pharmaceutical Sciences, Govt. Medical College, Kottayam, Kerala-686 008, India
2. Oman Medical College, Post Box.620, Postal Code: 130 Azaiba, Muscat, Sultanate of Oman.
3. Centre for Nanoscience & Nanotechnology, M.G. University, Kottayam, Kerala-686560, India

INTRODUCTION:

Cilostazol is chemically 6-[4-1-(cyclohexyl-1H-tetrazol-5-yl-butoxyl] 3-4-dihydro-2(1H)- quinolinone⁴. Cilostazol and its metabolites are cyclic adenosine monophosphate (cAMP) phosphodiesterase III inhibitors, inhibiting phosphodiesterase activity and suppressing cAMP degradation with a resultant increase in cAMP in platelets and blood vessels, leading to inhibition of platelet aggregation and vasodilation³. Therefore, Cilostazol is used for the treatment of intermittent claudication resulting from peripheral arterial disease. Cilostazol is commercially available as single dosage forms and combined dosage forms.

Cilostazol is official in United States Pharmacopoeia 2009. USP describes HPLC method for the assay of Cilostazol and its tablets, using a column packed with octadecysilanized silica gel with a mobile phase of water, acetonitrile and methanol (10:7:30) equipped with a 254nm detector and a flow rate of 1ml/min.

The Literature survey reveals few studies regarding determination of Cilostazol in pharmaceutical dosage forms and biological fluids. These works include HPLC, UV spectrophotometric and potentiometric methods to determine Cilostazol in pharmaceutical dosage forms³⁴. The assay of Cilostazol in the human plasma and mouse serum are also reported by HPLC methods.⁵–⁶

Today TLC is rapidly becoming a routine analytical technique due to its low operating costs, high sample throughput and the need for minimum sample preparation. The major advantage of HPTLC is that several samples can be run simultaneously using a small quantity of mobile phase and thus reducing the analysis time and cost per sample as compared to HPLC. The aim of the present study was to develop a simple, validated and rapid HPTLC method for routine analysis of Cilostazol in tablets. The HPTLC method was studied following official guidelines, evaluating the main parameters and the procedures and validated according to ICH guidelines.
MATERIALS AND METHODS:

Chemicals and Reagents
Cilostazol Reference Standard was supplied by Glenmark Pharmaceuticals Ltd, Mumbai, India. Cilostazol Tablets STILOZ-50, Glenmark Pharmaceuticals Ltd, Mumbai was procured from the market. Hexane, chloroform, acetone and methanol HPLC grade were procured from Merck, Germany.

HPTLC Instrumentation
The samples were spotted in the form of 6mm width with a Camag microlitre syringe on precoated silica gel aluminium plates 60 F254 (10 × 10 cm with 250 mm thickness, E. Merck), using a Camag Linomat 5 applicator. The plates were pre-washed with methanol and activated at 60°C for 5 min prior to chromatography. The slit dimension was kept at 4.00 × 0.30 mm(micro) and 20 mm/s scanning speed was employed. The mobile phase consisted of hexane:acetone:chloroform (5:2:3, v/v/v), and 10 ml of mobile phase was used. Linear ascending development was carried out in a 10×10 cm twin trough glass chamber (Camag, Muttenz, Switzerland) saturated with the mobile phase. The optimized chamber saturation time for the mobile phase was 30 min at room temperature (25°C±2). The length of the chromatogram run was approximately 8 cm, subsequent to development; the TLC plates were dried in a current of air with the help of an air dryer. Densitometric scanning was performed on a Camag TLC scanner 3 and was operated by WINCats software.

Preparation of standard solution and linearity study:
An accurately weighed quantity of 10 mg of Cilostazol was transferred to 10 ml volumetric flask, dissolved in methanol and made up to mark with the same solvent to obtain concentration 1µg/ µl. Standard solutions of 0.5, 1, 2, 5, 10, and 15 µl of Cilostazol was applied on TLC plate with the help of microlitre syringe, using Linomat 5 sample applicator to obtain the concentration of 0.5, 1, 2, 5, 10 and 15 µg spot⁻¹. The standard curves were evaluated for within day and day-to-day reproducibility. Each experiment was repeated six times.

Method validation:
Precision:
Repeatability of sample application and measurement of peak area were carried out using six replicates of the same spot (5µg spot⁻¹ of Cilostazol). The intra and inter-day variation for the determination of Cilostazol was carried out at three different concentration levels of 2, 5 and 10 µg per spot.

Limit of detection (LOD) and limit of quantification (LOQ):
In order to determine detection and quantification limit, Cilostazol concentrations in the lower part of the linear range of the calibration curve were used. Cilostazol solutions of 0.5, 1, 2, 5, 10 and 15 were prepared and applied in triplicate. The LOQ and LOD were calculated using equation LOD=3.3 × N/B and LOQ=10×N/B, where, N is standard deviation of the peak areas of the drugs (n=3), taken as a measure of noise, and B is the slope of the corresponding calibration curve.

Specificity:
The specificity of the method was ascertained by analyzing standard drug and sample. The spot of Cilostazol in sample was confirmed by comparing the Rf values and spectra of the spot with that of standard. The peak purity of Cilostazol was assessed by comparing the spectra at three levels, i.e., peak start(S), peak apex(M) and peak end(E) positions of the spot.

Ruggedness:
Ruggedness of the method was performed by spotting 5µg spot⁻¹ of Cilostazol by two different analyst keeping same experimental and environmental conditions.

Accuracy:
The analyzed samples were spiked with extra 80, 100 and 120% of the standard Cilostazol and the mixtures were analyzed by the proposed method. At each level of the amount, three determinations were performed. This was done to check the recovery of the drug at different levels in the formulations.

Robustness:
By introducing small changes in the mobile phase composition, the effects of the results were examined. Mobile phases having different compositions of hexane:acetone:chloroform was tried and chromatograms were run. The amount of mobile phase, temperature and relative humidity was varied in the range of ±5%. The plates were
prewashed by methanol and activated at 60±5°C for 2, 5 and 7 min prior to chromatography. Time from spotting to chromatography and from chromatography to scanning was varied from 0, 20 and 40 min.

**Application of proposed method to Tablet formulation:**
Twenty tablets of Cilostazol (STILOZ-50) were accurately weighed and powdered. Average weight of a tablet was determined. A quantity of tablet powder equivalent to 10 mg of Cilostazol was dissolved in methanol, sonicated for 20 minutes and made up to volume in a 10 ml volumetric flask. After filtration through 0.41 µm filter (millifilter, Milford, MA), 5µl of the solution was spotted followed by development and scanning as described in standard preparation. The analysis was repeated in triplicate.

**RESULTS AND DISCUSSION:**

**Development of optimum mobile phase:**
TLC procedure was optimized with a view to develop a sensitive and reproducible assay method for Cilostazol. Different mobile phases were tried by trial and error method. But, hexane:methanol 1:4, (v/v) gave good resolution for Cilostazol, but typical peak nature was missing. Finally, the mobile phase consisting of hexane:acetone:chloroform (5:2:3, (v/v/v) gave a sharp and well defined peak at Rf value of 0.15. Well defined spots were obtained when the chamber was saturated with the mobile phase for 30 min at room temperature. This system was selected for the study.

**Calibration curve:**
The linear regression data for the calibration curves showed good linear relationship over the concentration range 1-10µg spot⁻¹. Linear regression equation was found to be Y=1489x+4915 (r²=0.998).

**Validation of method:**

**Precision**
The precision of the developed HPTLC method was expressed in terms of % relative standard deviation (%RSD). The results depicted revealed high precision of the method presented in Table I.

**LOD and LOQ:**
Detection limit and quantification limit was calculated by the method described above. The LOQ and LOD were found to be 0.089 and 0.269µg spot⁻¹ respectively. This indicates the adequate sensitivity of the method.

**Recovery studies:**
The proposed method when used for extraction and subsequent estimation of Cilostazol from the pharmaceutical dosage form after spotting with 80, 100 and 120% of additional drug; afforded good recovery of Cilostazol. The amount of drug added and the % recovery are listed in Table II.

**Specificity:**
The peak purity of Cilostazol was assessed by comparing the spectra at peak start, peak apex and peak end positions of the spot, i.e., \( r^2 (S,M)=0.999 \) and \( r^2 (M,E)=0.9998 \). Good correlation \( (r^2=0.99) \) was also obtained between standard and sample spectra of Cilostazol.

**Robustness of the method:**
The standard deviation of peak areas was calculated for each parameter and %RSD was found to be less than 2%. The low values of %RSD values as shown in Table III. indicated robustness of the method.

**Analysis of the marketed formulation:**
A single spot at Rf 0.15 was observed in the chromatogram of the drug samples applied from the tablets. There was no interference from excipients. The % drug content and %RSD were calculated (Table IV). The low %RSD value indicated the suitability of this method for the routine analysis of Cilostazol in pharmaceutical dosage forms.
Figure I. Structure of Cilostazol

Table I. Intraday and inter-day precision studies

<table>
<thead>
<tr>
<th>Drug</th>
<th>Conc. µg/spot</th>
<th>Intra-day</th>
<th>Inter-day</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>%Amount found*</td>
<td>%RSD</td>
</tr>
<tr>
<td>Cilostazol</td>
<td>2</td>
<td>102.50</td>
<td>0.27</td>
</tr>
<tr>
<td></td>
<td>5</td>
<td>99.20</td>
<td>0.22</td>
</tr>
<tr>
<td></td>
<td>10</td>
<td>99.49</td>
<td>0.08</td>
</tr>
</tbody>
</table>

*mean of three estimations

Table II. Recovery Studies of Cilostazol

<table>
<thead>
<tr>
<th>Label claim of Cilostazol in STILOZ-50 (mg/tablet)</th>
<th>Amount of Standard drug added (%)</th>
<th>Drug recovered (%)</th>
<th>%RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>0</td>
<td>99.18</td>
<td>1.02</td>
</tr>
<tr>
<td>50</td>
<td>80</td>
<td>100.20</td>
<td>1.80</td>
</tr>
<tr>
<td>50</td>
<td>100</td>
<td>99.80</td>
<td>0.98</td>
</tr>
<tr>
<td>50</td>
<td>120</td>
<td>100.60</td>
<td>1.34</td>
</tr>
</tbody>
</table>

*mean of three estimations at each level

Table III. Robustness of the method*

<table>
<thead>
<tr>
<th>Parameter</th>
<th>S.D. of peak area</th>
<th>% RSD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mobile phase composition</td>
<td>62.07</td>
<td>0.50</td>
</tr>
<tr>
<td>Mobile phase volume</td>
<td>47.64</td>
<td>0.39</td>
</tr>
<tr>
<td>Development distance</td>
<td>40.07</td>
<td>0.32</td>
</tr>
<tr>
<td>Activation of TLC plate</td>
<td>58.62</td>
<td>0.47</td>
</tr>
<tr>
<td>Duration of saturation</td>
<td>55.02</td>
<td>0.45</td>
</tr>
<tr>
<td>Time from spotting to chromatography</td>
<td>62.19</td>
<td>0.50</td>
</tr>
<tr>
<td>Time from chromatography to scanning</td>
<td>63.96</td>
<td>0.52</td>
</tr>
</tbody>
</table>

*n=6

Table IV. Results of analysis of Cilostazol Tablet (STILOZ-50) by proposed method*

<table>
<thead>
<tr>
<th>Label Claim</th>
<th>Amount found ± SD</th>
<th>% of Label claim ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>50mg</td>
<td>49.97mg ± 0.08</td>
<td>99.95 ± 0.16</td>
</tr>
</tbody>
</table>

*n=3
CONCLUSION
The developed HPTLC technique was simple, specific, accurate, economical and validated based on ICH guidelines. Statistical analysis proves that the method is reproducible and selective for the analysis of Cilostazol as bulk drug and in pharmaceutical dosage forms. The method can be used to determine the purity of the drug available from various sources.
Acknowledgement:
The authors are thankful to the Glenmark Pharmaceuticals Ltd, Mumbai, India for providing gift sample of Cilostazol for the study.

REFERENCES:


